Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PET Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableActive Not RecruitingNCT01093612
What this trial is testing

Positron Emission Tomography in Women With Advanced HER2-Positive Breast Cancer

Who this might be right for
Breast CancerStage IV Breast Cancer
City of Hope Medical Center 18
Not applicableWithdrawnNCT03611205
What this trial is testing

Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy

Who this might be right for
Oropharyngeal Squamous Cell CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma
Ohio State University Comprehensive Cancer Center
Testing effectiveness (Phase 2)Active Not RecruitingNCT03161353
What this trial is testing

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

Who this might be right for
Breast Cancer
MedSIR 377
Early research (Phase 1)UnknownNCT02967666
What this trial is testing

Evaluation of PET/MRI Using a Somatostatin Analog Tracer as a Novel Approach to Detecting Pathology in High Risk TB-exposed Contacts

Who this might be right for
Tuberculosis, Pulmonary
National University Hospital, Singapore 30
Not applicableUnknownNCT03288597
What this trial is testing

Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms

Who this might be right for
Neuroendocrine Tumors
Peking University 146
Not applicableWithdrawnNCT04140513
What this trial is testing

Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer

Who this might be right for
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8Locally Advanced Oropharyngeal Squamous Cell Carcinoma+5 more
Ohio State University Comprehensive Cancer Center
Very early researchActive Not RecruitingNCT04401917
What this trial is testing

Evaluation of Neuroinflammation FNOS PET/CT in HIV (+) and (-) Subjects With OUD and Healthy Controls

Who this might be right for
HIV InfectionsOpioid Use
University of Pennsylvania 26
Not applicableActive Not RecruitingNCT02226276
What this trial is testing

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Who this might be right for
Bone MetastasesHER2-positive Breast CancerLiver Metastases+4 more
City of Hope Medical Center 10
Early research (Phase 1)Active Not RecruitingNCT07236112
What this trial is testing

Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer

Who this might be right for
Prostate Cancer
C Ray Therapeutics 6
Very early researchLooking for participantsNCT05549024
What this trial is testing

68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients

Who this might be right for
Breast CancerProstate CancerBrain Tumor+1 more
Peking Union Medical College Hospital 90
Testing effectiveness (Phase 2)Looking for participantsNCT07237269
What this trial is testing

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

Who this might be right for
Prostate Cancer
University of Nebraska 140
Large-scale testing (Phase 3)Looking for participantsNCT04147286
What this trial is testing

Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion

Who this might be right for
Tuberculosis, Pulmonary
University of Cape Town 220
Testing effectiveness (Phase 2)Study completedNCT00455741
What this trial is testing

Postmenopausal Women Estrogen and Progesterone Infusion

Who this might be right for
PostmenopauseAging
Massachusetts General Hospital 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06797622
What this trial is testing

Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positive Breast Cancer

Who this might be right for
Breast CancerMetastatic Breast Cancer
Fudan University 50
Not applicableStudy completedNCT05955833
What this trial is testing

89Zr-DFO*-Trastuzumab PET in Patients With Gastric or Breast Cancer - a Pilot Study

Who this might be right for
Breast CancerMetastatic Breast CancerHER2-positive Breast Cancer+3 more
Amsterdam UMC, location VUmc 6
Early research (Phase 1)Ended earlyNCT00520533
What this trial is testing

Study of Safety and Functional Imaging of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma

Who this might be right for
Renal Cell Carcinoma (RCC)
Ludwig Institute for Cancer Research 8
Testing effectiveness (Phase 2)Active Not RecruitingNCT05849298
What this trial is testing

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC

Who this might be right for
Prostatic Neoplasm
Novartis Pharmaceuticals 49
Not applicableStudy completedNCT04826211
What this trial is testing

Axillary Staging in Node Positive Breast Cancer Patients Receiving PST. SNB vs PET/MRI

Who this might be right for
Breast Cancer FemaleNode-positive Breast CancerSentinel Lymph Node
IRCCS San Raffaele 109
Testing effectiveness (Phase 2)Study completedNCT01142778
What this trial is testing

Bevacizumab Added to Trastuzumab Plus Docetaxel in the Neoadjuvant Setting in Participants With Early Stage HER2-Positive Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 152
Testing effectiveness (Phase 2)Active Not RecruitingNCT02398773
What this trial is testing

FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy

Who this might be right for
HER2/Neu NegativeProgesterone Receptor NegativeProgesterone Receptor Positive+1 more
National Cancer Institute (NCI) 99
Next Page